Abstract
The 4-hydrazinobenzoic acid derivatives were elaborated and evaluated of their in vitro cytotoxicity. Compounds 7, 9 and 10 showed potent inhibitory effects against HCT-116 and MCF-7 cancer cells giving IC50 ranged between 21.3 ± 4.1 and 28.3 ± 5.1 µM in comparison to doxorubicin. The active targets 7 and 9 exhibited very weak cytotoxicity on normal cells (RPE-1) and inhibited the proliferation of MCF-7 by the induction of apoptosis.
[Display omitted]
•A series of 4-Hydrazinylbenzoic derivatives were synthesized.•All targets were evaluated for in vitro cytotoxicity against HCT-116 and MCF-7 cancer cells.•6, 7 and 9 showed the best cytotoxicity against HCT-116 and MCF-7 cells.•7, 9 and 10 inhibited the proliferation of MCF-7 by the induction of apoptosis.•3D QSAR results were in agreement and correlated with the obtained anticancer findings.
Thirteen 4-hydrazinobenzoic acid derivatives were elaborated and characterized by spectral analyses (NMR and MS). Evaluation of their in vitro cytotoxic activity showed that some of the targets demonstrated potent inhibitory effects against HCT-116 and MCF-7 cancer cells. The IC50 values ranged between 21.3 ± 4.1 and 28.3 ± 5.1 µM, respectively, whereas those of doxorubicin (reference drug) ranged between 22.6 ± 3.9 and 19.7 ± 3.1 µM, respectively. The active targets 6, 7 and 9 exhibited very weak cytotoxicity on normal cells (RPE-1) and showed higher IC50 values against HCT-116 and MCF-7 cells in comparison to doxorubicin. Furthermore, compounds 7, 9 and 10 inhibited the proliferation of MCF-7 by the induction of apoptosis. The bioassay results in the regression plots generated in 3D QSAR models were in agreement and correlated with the anticancer results of the target molecules. The 4-hydazinobenzoic acid derivatives can be used as cornerstones for further structural modifications as future anticancer agents.